According to report, “In last year’s Goalkeepers Report, the Institute for Health Metrics and Evaluation predicted a drop of 14 % points in global vaccine coverage effectively erasing 25 years of progress in 25 weeks. New analysis from IHME demonstrates that the decline, while still unacceptable, was only half of what was anticipated” .
To ensure a truly equitable recovery from the pandemic, the co chairs call for long-term investments in health and economies like the ones that led to the rapid development of the Covid-19 vaccine to propel recovery efforts and get the world back on track to meet the Global Goals. The report also acknowledges that disparities caused by Covid-19 remain stark, and those who have been hardest hit by the pandemic will be the slowest to recover.
Vaccine against Covid-19 was developed in record time as a result of decades of investment, policies, and partnerships that established the infrastructure, talent, and ecosystems necessary to deploy them quickly, there has not been equitable distribution of the supply.
“We face the very real risk that in the future, wealthy countries and communities will begin treating Covid-19 as yet another disease of poverty. We can’t put the pandemic behind us until everyone, regardless of where they live, has access to vaccines.”
According to the report, 80% of all Covid-19 vaccines have been administered in high- and upper-middle-income countries to date, with some securing two to three times the number needed so they could cover boosters; less than 1% of doses have been administered in low-income countries.
“We must invest in local partners to strengthen the capacity of researchers and manufacturers in lower-income countries to create the vaccines and medicines they need,” said Gates Foundation CEO Mark Suzman. “The only way we will solve our greatest health challenges is by drawing on the innovation and talent of people all over the world.”
Covid-19 vaccine access has been strongly correlated with the locations where there is vaccine research and development, and manufacturing capability. Though Africa is home to 17% of the world’s population, for example, it has less than 1% of the world’s vaccine manufacturing capabilities.